Key Drivers
- Strong Liquidity
- Persistent Cash Burn
- Negative Equity
AIAI Summary
NVAX is now a high-risk platform-and-licensing investment—not a seasonal COVID-vaccine sales story—where upside depends on Sanofi/Pfizer converting Matrix-M and combination-vaccine programs into recurring milestones and royalties, while negative cash flow, debt, and partner-dependent execution leave little room for delays.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Cash Burn
- •Negative Equity
NVAX has strong liquidity and historical margins, but worsening losses, cash burn, rising debt, and negative equity make near-term financial risk elevated.
Price Behavior
Key Price Behavior Insights:
- •Strong Monthly Gain
- •Resistance Test
- •Key Support
NVAX gained about 20% over the last month and remains bullish above its 21-day average, with a breakout above $10.32–$10.34 favoring further upside while $9.20–$9.35 is key support.
Rebounded sharply from $9.23 to $10.11 after a pullback from resistance
Sentiment & News
Key News Insights:
- •Vaccine approvals
- •Matrix-M partnerships
- •Estimate uncertainty
Novavax gained attention from updated vaccine approvals and Matrix-M partnership prospects, though weak estimate revisions temper the bullish outlook.
Near-term sentiment is positive, but sustained upside depends on commercial execution and improving forecasts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings